Skip to content

Trastuzumab emtansine

Kadcyla (trastuzumab emtansine) is an antibody pharmaceutical. Trastuzumab emtansine was first approved as Kadcyla on 2013-11-15. It has been approved in Europe to treat breast neoplasms.
Trade Name Kadcyla
Common Name Trastuzumab emtansine
Indication breast neoplasms
Drug Class Monoclonal antibodies: humanized, tumors as target; maytansinoid derivatives
Trastuzumab emtansine
Get full access now